Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.53
-$0.01-1.13%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -15.07% | -3.36% | 7.60% | 6.09% | -2.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -50.73% | -42.43% | -34.41% | -32.84% | -26.53% |
| Operating Income | 50.73% | 42.43% | 34.41% | 32.84% | 26.53% |
| Income Before Tax | 51.98% | 42.52% | 33.62% | 31.11% | 24.68% |
| Income Tax Expenses | -35.20% | -1.73% | -3.08% | 102.94% | -19.73% |
| Earnings from Continuing Operations | 51.97% | 42.50% | 33.60% | 31.07% | 24.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.97% | 42.50% | 33.60% | 31.07% | 24.68% |
| EBIT | 50.73% | 42.43% | 34.41% | 32.84% | 26.53% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 82.27% | 71.32% | 63.16% | 58.13% | 50.99% |
| Normalized Basic EPS | 82.27% | 71.33% | 63.17% | 58.15% | 50.98% |
| EPS Diluted | 82.27% | 71.32% | 63.16% | 58.13% | 50.99% |
| Normalized Diluted EPS | 82.27% | 71.33% | 63.17% | 58.15% | 50.98% |
| Average Basic Shares Outstanding | 242.09% | 147.73% | 115.70% | 75.46% | 56.55% |
| Average Diluted Shares Outstanding | 242.09% | 147.73% | 115.70% | 75.46% | 56.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |